Soluble Receptor for Advanced Glycation End Products (sRAGE) Isoforms Predict Changes in Resting Energy Expenditure in Adults with Obesity during Weight Loss. Issue 5 (29th March 2022)

• Record Type: Journal Article
• Authors: Popp, Collin J; Zhou, Boyan; Manigrasso, Michaele B; Li, Huilin; Curran, Margaret; Hu, Lu; St-Jules, David E; Alemán, José O; Vanegas, Sally M; Jay, Melanie; Bergman, Michael; Segal, Eran; Sevick, Mary A; Schmidt, Ann M
• Is Part Of: Current developments in nutrition. Volume 6:Issue 5(2022)
• Publication Date: 2022-03-29
• Subjects: precision nutrition -- caloric restriction -- resting metabolic rate -- metabolic adaptation -- energy balance; Nutrition -- Periodicals; Nutritional Physiological Phenomena; Nutrition; Periodicals; Periodicals; Fulltext; Internet Resources; Periodicals; 612.3
• DOI: 10.1093/cdn/nzac046
• Languages: English
• ISSNs: 2475-2991

Abstract

Abstract: Background: Accruing evidence indicates that accumulation of advanced glycation end products (AGEs) and activation of the receptor for AGEs (RAGE) play a significant role in obesity and type 2 diabetes. The concentrations of circulating RAGE isoforms, such as soluble RAGE (sRAGE), cleaved RAGE (cRAGE), and endogenous secretory RAGE (esRAGE), collectively sRAGE isoforms, may be implicit in weight loss and energy compensation resulting from caloric restriction. Objectives: We aimed to evaluate whether baseline concentrations of sRAGE isoforms predicted changes (∆) in body composition [fat mass (FM), fat-free mass (FFM)], resting energy expenditure (REE), and adaptive thermogenesis (AT) during weight loss. Methods: Data were collected during a behavioral weight loss intervention in adults with obesity. At baseline and 3 mo, participants were assessed for body composition (bioelectrical impedance analysis) and REE (indirect calorimetry), and plasma was assayed for concentrations of sRAGE isoforms (sRAGE, esRAGE, cRAGE). AT was calculated using various mathematical models that included measured and predicted REE. A linear regression model that adjusted for age, sex, glycated hemoglobin (HbA1c), and randomization arm was used to test the associations between sRAGE isoforms and metabolic outcomes. Results: Participants ( n = 41; 70% female; mean ± SD age: 57 ± 11 y; BMI: 38.7 ± 3.4 kg/m 2 ) experienced modest and variable weight loss over 3 mo. Although baseline sRAGE isoforms did not predict changes in ∆FM or ∆FFM, all baseline sRAGE isoforms were positively associated with ∆REE at 3 mo. Baseline esRAGE was positively associated with AT in some, but not all, AT models. The association between sRAGE isoforms and energy expenditure was independent of HbA1c, suggesting that the relation was unrelated to glycemia. Conclusions: This study demonstrates a novel link between RAGE and energy expenditure in human participants undergoing weight loss. This trial was registered at clinicaltrials.gov as NCT03336411. Abstract : Soluble (s)RAGE isoforms, specifically endogenous secretory RAGE, predicts changes in resting energy expenditure in adults with obesity following weight loss.